Agritech company Supplant, funded by Y-Combinator, goes up for sale following a move into administration.
In the world of agritech, Supplant, a Cambridge-based company specializing in creating sugars from fibre for use in confectionery items, is making headlines. The company, founded in 2017 by Dr. Tom Simmons, has been putting forth a claim that their products have a lower impact on blood-sugar levels.
Supplant's journey has been marked by significant funding rounds. The company's largest funding round was in 2021, where it raised $24m. Prior to this, in 2018, it secured a $5M seed round investment via Y-Combinator. Since its launch, Supplant has raised over £25m in funding.
The company's products are produced via a deal with a contract manufacturer in Asia. Notable investors backing Supplant include Manta Ray, Khosla, Felicis, EQT, Coatue, and Y-Combinator. However, the company did not respond to a request for comment.
Recently, Supplant has been put into administration, and it is now seeking a rescue buyer. The firm is offering its services to potential buyers over £2.5m. The company's revenues were approximately $1m, and it had an outpost in the US and employed around three dozen staff at its peak.
The insolvency marketplace listing and the firm’s recent financial struggles indicate that the market for potential buyers is niche and focused on investors with an appetite for deep technology in agriculture, as well as those experienced in rescuing or scaling early-stage agtech companies.
Potential buyers for Supplant could include agritech and AgTech venture capital investors such as AgFunder, The Yield Lab, and Ag Startup Engine, who focus on innovative agriculture startups. These investors may see Supplant’s technology and data science capabilities as valuable assets.
Strategic players in vertical farming or related agtech sectors looking to expand capabilities or geographic reach might also consider purchasing Supplant. These could include large agribusiness companies, food technology firms, or other innovators seeking to integrate controlled-environment agriculture.
Private equity or turnaround investors interested in distressed or administratively challenged firms in fast-growing agtech markets might also be potential buyers, given Supplant’s insolvency status and urgent need for scale and capital infusion to improve unit economics.
Supplant holds an expansive intellectual property portfolio, including 20 granted patents and 40 patent pending applications. The company has also developed its own flour for use in pasta, which claims to have fewer calories and as much as three times as much fibre.
As Supplant navigates this challenging phase, the agritech industry waits with bated breath to see who will step forward to take the reins and continue the company's groundbreaking work in fibre-based sugars.
- Supplant's intellectual property portfolio, which includes 20 granted patents and 40 patent pending applications, showcases the company's significant investment in technology.
- Potential buyers from the agritech industry, such as AgFunder, The Yield Lab, and Ag Startup Engine, might be drawn to Supplant due to its innovative technology and data science capabilities.
